• Explore /
  • Poster
  • / CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).

CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).

Abstract Poster

Authors

null

Jeremy S. Abramson

Massachusetts General Hospital Cancer Center, Boston, MA

Jeremy S. Abramson , Maria Lia Palomba , Leo I. Gordon , Matthew Alexander Lunning , Jon E. Arnason , Andres Forero-Torres , Michael Wang , Tina M. Albertson , Tara Allen , Claire Sutherland , Benhuai Xie , Jacob Garcia , Tanya Siddiqi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02631044

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7513)

DOI

10.1200/JCO.2017.35.15_suppl.7513

Abstract #

7513

Poster Bd #

275

Abstract Disclosures

Similar Posters

First Author: Alison R. Sehgal

First Author: Sarah Marie Larson

First Author: Alison Sehgal

First Author: Larry D. Anderson, Jr